We Made the 2024 Access to Medicine Index List

We've been ranked in the top 5 in the 2024 Access to Medicine Index! We're committed to helping expand access to essential medicines and vaccines for patients everywhere. Learn more about our progress.

The Race Against Drug-Resistant Infections

While undergoing treatment for lymphoma, antibiotics saved Kristin's life when she developed neutropenic sepsis, a life-threatening complication of some cancer treatments that can lead to overwhelming infection.

Anchored in Trust: Connection Matters

Watch some key moments from our annual DE&I summit to see how we're dedicated to building a more inclusive future for everyone. Through meaningful connections built on trust, we create an environment where everyone can feel seen, heard and cared for.

Targeting Cancer with Antibody-drug Conjugates

Pfizer scientists are working to unlock the full potential of ADCs to improve outcomes for patients across many different cancer types and change the future of cancer care.

Dear Scientist, I Was Diagnosed with Stage 4 Lung Cancer

In our latest Dear Scientist episode, Deanna meets Pfizer's Head of ADC Discovery, Scott Peterson, to learn what is on the horizon for potential treatments, innovation, and hope.

Connected. Active. Involved.

Welcome to the official website for retirees of Pfizer and its legacy organizations.

Pfizer News

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
November 14, 2024
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
November 04, 2024
Pfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance
October 29, 2024
Advisory Committee on Immunization Practices Recommends PREVNAR® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older
October 23, 2024
U.S. FDA Approves Pfizer's RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease
October 22, 2024
Tim Buckley Elected to Pfizer's Board of Directors
October 15, 2024
U.S. FDA Approves Pfizer's HYMPAVZI (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors
October 11, 2024
Pfizer's TALZENNA® in Combination with XTANDI® Prolongs Overall Survival in Phase 3 TALAPRO-2 Triald
October 10, 2024
Pfizer Declares Fourth-Quarter 2024 Dividend
October 09, 2024
Pfizer to Showcase Scientific Advancements in Respiratory and Other Infectious Diseases at IDWeek 2024
October 08, 2024
Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets
September 25, 2024
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
September 20, 2024
Pfizer Invites Public to View and Listen to Webcast of October 29 Conference Call with Analysts
September 17, 2024
Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexi
September 14, 2024
Pfizer's BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
September 14, 2024
Pfizer Highlights Diverse Oncology Portfolio and Combination Approaches at ESMO 2024
September 11, 2024
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
August 28, 2024
Pfizer Launches PfizerForAllTM, a Digital Platform that Helps Simplify Access to Healthcare
August 27, 2024
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
August 22, 2024
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
August 16, 2024
Pfizer Announces Top-Line Results of ABRYSVO® for RSV in Immunocompromised Adults
August 12, 2024
Pfizer Reports Strong Second-Quarter 2024 Results And Raises 2024 Guidance
July 30, 2024
European Commission Approves Pfizer's DURVEQTIX® (fidanacogene elaparvovec), a One-Time Gene Therapy for Adults with Hemophilia B
July 25, 2024
Pfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate
July 24, 2024
Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron
July 11, 2024
Pfizer to Launch Process to Identify a Successor for Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development
July 09, 2024
Cyrus Taraporevala Elected to Pfizer's Board of Directors
July 01, 2024
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
June 27, 2024
Pfizer Declares Third-Quarter 2024 Dividend
June 26, 2024
Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts
June 18, 2024
ELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma
June 16, 2024
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
June 14, 2024
Pfizer's ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
June 01, 2024
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
June 01, 2024
Pfizer's LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression
May 31, 2024

Join the Pfizer Plus Community Corner

When you join the PfizerPlus.com community, you can get access to our special “member’s only” features including:

  • Member Only Content
  • Email Updates
  • PfizerPlus.com Community